Financial comparisons Prime Medicine, Inc.
Equities
PRME
US74168J1016
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.790 USD | +2.43% |
|
+7.06% | +9.22% |
| 19/03 | Prime Medicine, Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM | |
| 12/03 | Oppenheimer Initiates Prime Medicine at Outperform With $11 Price Target | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 4.63M | -4,342.44% | -4,498.06% | -146.81% | -62.83% | 0.88x | |
| 4.23B | 30.41% | 24.81% | 20.15% | 17.36% | -3.18x | |
| 6.5B | 42.13% | 52.64% | 28.56% | 20.88% | -0.99x | |
| 606M | -210.54% | -205.59% | -249.28% | - | 0.72x | |
| 3.37B | -39.59% | -48.95% | -5.88% | -5.1% | 6.99x | |
| 2.56B | 17.97% | 25.37% | 11.65% | 8.43% | -0.66x | |
| 3.69B | 25.89% | 28.63% | 17.53% | 9.99% | -1.51x | |
| 291M | -24.22% | -26.28% | -8.94% | -4.69% | -2.82x | |
| 265M | -13.8% | -7.18% | -9.46% | -9.11% | 18.95x | |
| 958M | -30.08% | -31.31% | -42.49% | - | 2.15x | |
| 2.32B | 33.73% | 37.59% | 35.53% | 27.02% | -1.18x | |
| 463M | 21.89% | 3.81% | 24.87% | 11.13% | 2.2x | |
| 829M | -0.2% | 11.86% | -0.5% | - | -6.61x | |
| 1.16B | 23.46% | 22.49% | 20.1% | 13% | 0.68x | |
| 88.04M | -891.6% | -695.44% | - | -55.55% | 0.05x | |
| 113M | -310.18% | -226% | - | - | - | |
| Average | 1.72B | -354.2% | -345.73% | -21.78% | -2.46% | 1.05x | |
| Weighted average by Cap. | 2.76B | -53.73% | -45.39% | -18.22% | 8.3% | 0.58x |
- Stock Market
- Equities
- PRME Stock
- Sector Prime Medicine, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition